Thursday, August 09, 2018
New Study Views Cancer Treatment as a Game to Find Strategies That Improve Patient Outcomes

Game theory can be utilized to identify potential flaws in current cancer treatment approaches and suggest new strategies to improve outcomes in patients with metastatic cancer. A new study authored by researchers from Moffitt Cancer Center and Maastricht University challenges the decades old standard of treatment for metastatic cancers in which drugs are typically administered continuously at the maximum-tolerated dose until the tumor progresses. ..

Read More
Tuesday, June 05, 2018
FCS Research Published at American Society of Clinical Oncology’s Annual Meeting

Thirty-six research studies co-authored by Fort Myers-based Florida Cancer Specialists & Research Institute physicians have been published or presented at the 2018 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois, June 1-5, 2018. ..

Read More
Thursday, May 31, 2018
Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

Roswell Park Comprehensive Cancer Center (Roswell Park) and Hemispherx Biopharma, Inc. plan to expand their existing scientific collaboration to advance the clinical development of Ampligen – an investigational immune-enhancing TLR3 agonist – which has shown promise in preclinical studies when combined with checkpoint inhibitors to treat certain cancers. ..

Read More
Tuesday, May 01, 2018
Florida Cancer Centers Awarded $1.36 Million to Fight Pancreatic Cancer

The Florida Department of Health's James and Esther King Biomedical Research Program has armed Moffitt Cancer Center, University of Florida Health Cancer Center - Gainesville, Sylvester Comprehensive Cancer Center at the University of Miami and numerous collaborating centers with $1.36 million to address cancer disparities and improve outcomes and care for individuals affected by pancreatic cancer. ..

Read More
Tuesday, April 10, 2018
Scripps Florida Researchers Awarded $2.875 Million to Destroy Common Form of Leukemia

Christoph Rader, Ph.D., associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia. Doctors diagnose more than 20,000 people a year in the United States with chronic lymphocytic leukemia. ..

Read More
Wednesday, November 11, 2015
Couple Pledges $1 Million to Nova Southeastern University to Help Fight Cancer

For Mike and Alice Jackson, cancer is personal; so much so that they are joining with Nova Southeastern University (NSU) researchers in the fight against one of the nation’s deadliest diseases. The Jacksons announced a $1 million personal pledge to support NSU’s cancer research. ..

Read More
Thursday, January 23, 2014
Moffitt Cancer Center Instrumental in FDA Approval of Revolutionary Two-Drug Combo to Treat Advanced Melanoma

Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for the treatment of advanced melanoma – melanoma that cannot be removed surgically or has spread to other areas of the body. The newly FDA-approved therapy, Mekinist (trametinib) in combination with Tafinlar (dabrafenib), is one of the biggest advancements in melanoma treatment in the past 30 years. ..

Read More
Friday, May 17, 2013
USF studies promise breast cancer breakthrough

As the news of Angelina Jolie brings awareness to the fight against breast cancer there is a major medical breakthrough thanks to a nationwide study with the largest number of participants at the University of South Florida's Breast Health. ..

Read More
Thursday, April 19, 2012
Moffitt Cancer Center Researchers Find Cancer Therapies Affect Cognitive Functioning among Breast Cancer Survivors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer. They published their study in the April 1 issue of CANCER. ..

Read More
Monday, April 02, 2012
Moffitt Cancer Center Researchers Validate New Staging Classifications for Neuroendocrine Pancreatic Tumor Surgery Response

Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be candidates for surgery. The results of their study were published in a recent issue of the Annals of Surgery. ..

Read More